ERBB2 and breast cancer: In the METABRIC cohort, PRR11 copy number gain or amplification predicted shorter disease-free survival of patients with ER+/HER2− breast cancer treated with antiestrogens (HR = 1.408; 95% CI, 1.029–1.926; Fig. 2c).